Savara and Serendex Join Forces to Develop Drugs for Rare Lung Diseases
21 June 2016

On-the-rise pharmaceutical company, Savara Pharmaceuticals has acquired the assets of Serendex Pharmaceuticals.

Cancer Vaccine for Triple Negative Breast Cancer Begins
21 June 2016

TapImmune announced the commencement of dosing its first patient in a Phase 2 trial for triple negative breast cancer with its cancer vaccine TPIV 200.

5 Year AA Amyloidosis Study Fails to Meet Primary Endpoint
21 June 2016

A phase 3 AA amyloidosis study has failed to meet its primary endpoint.
 

FDA to review Mitsubishi’s ALS drug
21 June 2016

US regulators have agreed to review Mitsubishi Tanabe's application to market edaravone for the treatment of amyotrophic lateral sclerosis (ALS), a rapidly progressive neurological disease.

Breast Cancer Cells Use Newfound Pathway to Survive Low Oxygen Levels in Tumors
20 June 2016

Researchers have identified a new signaling pathway that helps cancer cells cope with the lack of oxygen found inside tumors.

5 Year Data with Stensiq to Treat Hypophosphatasia Published
20 June 2016

Five year data showing the efficacy and safety of Strensiq (asfotase alfa) to treat children with hypophosphatasia (HPP) was published this week in the Journal of Clinical Investigations.

Data back Merck’s Keytruda for first-line NSCLC
17 June 2016

Merck's Keytruda has hit targets in a Phase III trial investigating its safety and efficacy in patients with previously untreated lung cancer, backing its use in the first-line treatment setting.

Vertex’ CF drug Orkambi turned down for NHS use
17 June 2016

Patients with cystic fibrosis will not be getting access to Vertex' Orkambi on the NHS in England Wales, after the National Institute for Health and Care Excellence stuck with its prior decision th